Inactive Instrument

Lidds AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Lidds AB

Financials

Sales 2022 1.89M 178K 13.75M Sales 2023 - Capitalization 7.37M 696K 53.66M
Net income 2022 -36M -3.4M -262M Net income 2023 -40M -3.78M -291M EV / Sales 2022 30.5 x
Net cash position 2022 1.26M 119K 9.2M Net cash position 2023 13.51M 1.28M 98.4M EV / Sales 2023 -
P/E ratio 2022
-1.58 x
P/E ratio 2023
-0.17 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 82.4%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 53 30/11/21
Corporate Officer/Principal - 30/09/22
Corporate Officer/Principal 61 31/12/03
Members of the board TitleAgeSince
Director/Board Member 62 01-08
Director/Board Member 66 01-08
Chairman 48 31/12/16
More insiders
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Company’s portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
Calendar
More about the company